<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38522030</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-4141</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of immunology</Title><ISOAbbreviation>Eur J Immunol</ISOAbbreviation></Journal><ArticleTitle>Age-related transcript changes in type I interferon signaling in children and adolescents with long COVID.</ArticleTitle><Pagination><StartPage>e2350682</StartPage><MedlinePgn>e2350682</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/eji.202350682</ELocationID><Abstract><AbstractText>SARS-CoV-2 typically causes mild symptoms in children, but evidence suggests that persistent immunopathological changes may lead to long COVID (LC). To explore the interplay between LC and innate immunity, we assessed the type I interferon (IFN-I) response in children and adolescents with LC symptoms (LC; n = 28). This was compared with age-matched SARS-CoV-2 recovered participants without LC symptoms (MC; n = 28) and healthy controls (HC; n = 18). We measured the mRNA expression of IFN-I (IFN-&#x3b1;/&#x3b2;/&#x3b5;/&#x3c9;), IFN-I receptor (IFNAR1/2), and ISGs (ISG15, ISG56, MxA, IFI27, BST2, LY6E, OAS1, OAS2, OAS3, and MDA5) in PBMCs collected 3-6 months after COVID-19. LC adolescents (12-17 years) had higher transcript levels of IFN-&#x3b2;, IFN-&#x3b5;, and IFN-&#x3c9; than HC, whereas LC children (6-11 years) had lower levels than HC. In adolescents, increased levels of IFN-&#x3b1;, IFN-&#x3b2;, and IFN-&#x3c9; mRNAs were found in the LC group compared with MC, while lower levels were observed in LC children than MC. Adolescents with neurological symptoms had higher IFN-&#x3b1;/&#x3b2; mRNA levels than MC. LC and MC participants showed decreased expression of ISGs and IFNAR1, but increased expression of IFNAR2, than HC. Our results show age-related changes in the expression of transcripts involved in the IFN-I signaling pathway in children and adolescents with LC.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley&#x2010;VCH GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Fracella</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Mancino</LastName><ForeName>Enrica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nenna</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virgillito</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frasca</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Auria</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3804-2946</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrarca</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Regina</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matera</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Mattia</LastName><ForeName>Greta</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caputo</LastName><ForeName>Beniamino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierangeli</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viscidi</LastName><ForeName>Raphael P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Midulla</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Scagnolari</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1044-1478</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>EU</Agency><Country/></Grant><Grant><GrantID>PE00000007</GrantID><Agency>NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases</Agency><Country/></Grant><Grant><Agency>Sapienza University of Rome</Agency><Country/></Grant><Grant><GrantID>RM1221814ED155C3</GrantID><Agency>Progetti Ricerca-Progetti Medi</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Immunol</MedlineTA><NlmUniqueID>1273201</NlmUniqueID><ISSNLinking>0014-2980</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescents</Keyword><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">ISGs</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Neutralizing autoantibodies to interferon</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">Type I interferon</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>24</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>24</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38522030</ArticleId><ArticleId IdType="doi">10.1002/eji.202350682</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. and Topol, E. J., Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023. 21: 133&#x2013;146.</Citation></Reference><Reference><Citation>Proal, A. D. and Van Elzakker, M. B., Long COVID or post&#x2010;acute sequelae of COVID&#x2010;19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021. 12: 698169.</Citation></Reference><Reference><Citation>Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re'em, Y., Redfield, S. et&#xa0;al., Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021. 38: 101019.</Citation></Reference><Reference><Citation>Lopez&#x2010;Leon, S., Wegman&#x2010;Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P. A., Cuapio, A. and Villapol, S., More than 50 long&#x2010;term effects of COVID&#x2010;19: a systematic review and meta&#x2010;analysis. Sci. Rep. 2021. 11: 16144.</Citation></Reference><Reference><Citation>Michelen, M., Manoharan, L., Elkheir, N., Cheng, V., Dagens, A., Hastie, C., O'Hara, M. et&#xa0;al., Characterising long COVID: a living systematic review. BMJ Glob. Health. 2021. 6: e005427.</Citation></Reference><Reference><Citation>Loretelli, C., Abdelsalam, A., D'Addio, F., Ben Nasr, M., Assi, E., Usuelli, V., Maestroni, A. et&#xa0;al., PD&#x2010;1 blockade counteracts post&#x2010;COVID&#x2010;19 immune abnormalities and stimulates the anti&#x2010;SARS&#x2010;CoV&#x2010;2 immune response. JCI Insight. 2021. 6: e146701.</Citation></Reference><Reference><Citation>Chou, J., Thomas, P. G. and Randolph, A. G., Immunology of SARS&#x2010;CoV&#x2010;2 infection in children. Nat. Immunol. 2022. 23: 177&#x2013;185.</Citation></Reference><Reference><Citation>Kang, C. K., Shin, H. M., Park, W. B. and Kim, H. R., Why are children less affected than adults by severe acute respiratory syndrome coronavirus 2 infection? Cell Mol. Immunol. 2022. 19: 555&#x2013;557.</Citation></Reference><Reference><Citation>Okomo, U., Idoko, O. T. and Kampmann, B., The burden of viral respiratory infections in young children in low&#x2010;resource settings. Lancet Glob Health. 2020. 8: e454&#x2013;e455.</Citation></Reference><Reference><Citation>Tregoning, J. S. and Schwarze, J., Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev. 2010. 23: 74&#x2013;98.</Citation></Reference><Reference><Citation>Dowell, A. C., Butler, M. S., Jinks, E., Tut, G., Lancaster, T., Sylla, P., Begum, J. et&#xa0;al., Children develop robust and sustained cross&#x2010;reactive spike&#x2010;specific immune responses to SARS&#x2010;CoV&#x2010;2 infection. Nat Immunol. 2022. 23: 40&#x2013;49.</Citation></Reference><Reference><Citation>Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S. et&#xa0;al., Antigen&#x2010;specific adaptive immunity to SARS&#x2010;CoV&#x2010;2 in acute COVID&#x2010;19 and associations with age and disease severity. Cell. 2020. 183: 996&#x2013;1012.e19.</Citation></Reference><Reference><Citation>Yoshida, M., Worlock, K. B., Huang, N., Lindeboom, R. G. H., Butler, C. R., Kumasaka, N., Dominguez Conde, C. et&#xa0;al., Local and systemic responses to SARS&#x2010;CoV&#x2010;2 infection in children and adults. Nature. 2022. 602: 321&#x2013;327.</Citation></Reference><Reference><Citation>Kumar, A., Ishida, R., Strilets, T., Cole, J., Lopez&#x2010;Orozco, J., Fayad, N., Felix&#x2010;Lopez, A. et&#xa0;al., SARS&#x2010;CoV&#x2010;2 nonstructural protein 1 inhibits the interferon response by causing depletion of key host signaling factors. J. Virol. 2021. 95: e0026621.</Citation></Reference><Reference><Citation>Min, Y. Q., Huang, M., Sun, X., Deng, F., Wang, H. and Ning, Y. J., Immune evasion of SARS&#x2010;CoV&#x2010;2 from interferon antiviral system. Comput. Struct. Biotechnol. J. 2021. 19: 4217&#x2013;4225.</Citation></Reference><Reference><Citation>McNab, F., Mayer&#x2010;Barber, K., Sher, A., Wack, A. and O'Garra, A., Type I interferons in infectious disease. Nat. Rev. Immunol. 2015. 15: 87&#x2013;103.</Citation></Reference><Reference><Citation>Freitas, R. S., Crum, T. F. and Parvatiyar, K., SARS&#x2010;CoV&#x2010;2 spike antagonizes innate antiviral immunity by targeting interferon regulatory factor 3. Front. Cell. Infect. Microbiol. 2022. 11: 789462.</Citation></Reference><Reference><Citation>Han, L., Zhuang, M. W., Deng, J., Zheng, Y., Zhang, J., Nan, M. L., Zhang, X. J. et&#xa0;al., SARS&#x2010;CoV&#x2010;2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG&#x2010;I/MDA&#x2010;5&#x2010;MAVS, TLR3&#x2010;TRIF, and cGAS&#x2010;STING signaling pathways. J. Med. Virol. 2021. 93: 5376&#x2013;5389.</Citation></Reference><Reference><Citation>Znaidia, M., Demeret, C., van der Werf, S. and Komarova, A. V., Characterization of SARS&#x2010;CoV&#x2010;2 evasion: interferon pathway and therapeutic options. Viruses. 2022. 14: 1247.</Citation></Reference><Reference><Citation>Asadi&#x2010;Pooya, A. A., Nemati, H., Shahisavandi, M., Akbari, A., Emami, A., Lotfi, M., Rostamihosseinkhani, M. et&#xa0;al., Long COVID in children and adolescents. World J. Pediatr. 2021. 17: 495&#x2013;499.</Citation></Reference><Reference><Citation>Lopez&#x2010;Leon, S., Wegman&#x2010;Ostrosky, T., Ayuzo Del Valle, N. C., Perelman, C., Sepulveda, R., Rebolledo, P. A., Cuapio, A. et&#xa0;al., Long&#x2010;COVID in children and adolescents: a systematic review and meta&#x2010;analyses. Sci. Rep. 2022. 12: 9950.</Citation></Reference><Reference><Citation>Wong, A. C., Devason, A. S., Umana, I. C., Cox, T. O., Dohnalov&#xe1;, L., Litichevskiy, L., Perla, J. et&#xa0;al., Serotonin reduction in post&#x2010;acute sequelae of viral infection. Cell. 2023. 186: 4851&#x2013;4867.e20.</Citation></Reference><Reference><Citation>Martin&#x2010;Sancho, L., Lewinski, M. K., Pache, L., Stoneham, C. A., Yin, X., Becker, M. E., Pratt, D. et&#xa0;al., Functional landscape of SARS&#x2010;CoV&#x2010;2 cellular restriction. Mol. Cell. 2021. 81: 2656&#x2013;2668.e8.</Citation></Reference><Reference><Citation>Gea&#x2010;Mallorqu&#xed;, E., Mapping host restriction of SARS&#x2010;CoV&#x2010;2. Nat. Rev. Immunol. 2021. 21: 3.</Citation></Reference><Reference><Citation>Danziger, O., Patel, R. S., DeGrace, E. J., Rosen, M. R. and Rosenberg, B. R., Inducible CRISPR activation screen for interferon&#x2010;stimulated genes identifies OAS1 as a SARS&#x2010;CoV&#x2010;2 restriction factor. PLoS Pathog. 2022. 18: e1010464.</Citation></Reference><Reference><Citation>Frasca, F., Scordio, M., Santinelli, L., Gabriele, L., Gandini, O., Criniti, A., Pierangeli, A. et&#xa0;al., Anti&#x2010;IFN&#x2010;&#x3b1;/&#x2010;&#x3c9; neutralizing antibodies from COVID&#x2010;19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. Eur. J. Immunol. 2022. 52: 1120&#x2013;1128.</Citation></Reference><Reference><Citation>Scordio, M., Frasca, F., Santinelli, L., Sorrentino, L., Pierangeli, A., Turriziani, O., Mastroianni, C. M. et&#xa0;al., High frequency of neutralizing antibodies to type I interferon in HIV&#x2010;1 patients hospitalized for COVID&#x2010;19. Clin. Immunol. 2022. 241: 109068.</Citation></Reference><Reference><Citation>Bastard, P., Rosen, L. B., Zhang, Q., Michailidis, E., Hoffmann, H. H., Zhang, Y., Dorgham, K. et&#xa0;al., Autoantibodies against type I IFNs in patients with life&#x2010;threatening COVID&#x2010;19. Science. 2020. 370: eabd4585.</Citation></Reference><Reference><Citation>Philippot, Q., Fekkar, A., Gervais, A., Le Voyer, T., Boers, L. S., Conil, C., Bizien, L. et&#xa0;al., Autoantibodies neutralizing type I IFNs in the bronchoalveolar lavage of at least 10% of patients during life&#x2010;threatening COVID&#x2010;19 pneumonia. J. Clin. Immunol. 2023. 43: 1093&#x2013;1103.</Citation></Reference><Reference><Citation>National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 2021. (February 22, 2021) https://www.cdc.gov/ncbddd/childdevelopment/positiveparenting/middle.html</Citation></Reference><Reference><Citation>Lebon, P., Ponsot, G., Aicardi, J., Gouti&#xe8;res, F. and Arthuis, M., Early intrathecal synthesis of interferon in herpes encephalitis. Biomedicine. 1979. 31: 267&#x2013;271.</Citation></Reference><Reference><Citation>Buonsenso, D., Munblit, D., De Rose, C., Sinatti, D., Ricchiuto, A., Carfi, A. and Valentini, P., Preliminary evidence on long COVID in children. Acta. Paediatr. 2021. 110: 2208&#x2013;2211.</Citation></Reference><Reference><Citation>Pierangeli, A., Gentile, M., Oliveto, G., Frasca, F., Sorrentino, L., Matera, L., Nenna, R. et&#xa0;al., Comparison by age of the local interferon response to SARS&#x2010;CoV&#x2010;2 suggests a role for IFN&#x2010;&#x3b5; and &#x2010;&#x3c9;. Front. Immunol. 2022. 13: 873232.</Citation></Reference><Reference><Citation>Mallapaty, S., Kids and COVID: why young immune systems are still on top. Nature. 2021. 597: 166&#x2013;168.</Citation></Reference><Reference><Citation>Sposito, B., Broggi, A., Pandolfi, L., Crotta, S., Clementi, N., Ferrarese, R., Sisti, S., et&#xa0;al., The interferon landscape along the respiratory tract impacts the severity of COVID&#x2010;19. Cell. 2021. 184: 4953&#x2013;4968.e16.</Citation></Reference><Reference><Citation>Zanoni, I., Interfering with SARS&#x2010;CoV&#x2010;2: are interferons friends or foes in COVID&#x2010;19? Curr. Opin. Virol. 2021. 50: 119&#x2013;127.</Citation></Reference><Reference><Citation>Vono, M., Huttner, A., Lemeille, S., Martinez&#x2010;Murillo, P., Meyer, B., Baggio, S., Sharma, S. et&#xa0;al., Robust innate responses to SARS&#x2010;CoV&#x2010;2 in children resolve faster than in adults without compromising adaptive immunity. Cell Rep. 2021. 37: 109773.</Citation></Reference><Reference><Citation>Zhou, R., To, K. K., Wong, Y. C., Liu, L., Zhou, B., Li, X., Huang, H. et&#xa0;al., Acute SARS&#x2010;CoV&#x2010;2 infection impairs dendritic cell and T cell responses. Immunity. 2020. 53: 864&#x2013;877.e5.</Citation></Reference><Reference><Citation>Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H. and Moulton, V. R., Aging, immunity, and COVID&#x2010;19: how age influences the host immune response to coronavirus infections? Front. Physiol. 2021. 11: 571416.</Citation></Reference><Reference><Citation>Bozack, A. K., Rifas&#x2010;Shiman, S. L., Gold, D. R., Laubach, Z. M., Perng, W., Hivert, M. F. and Cardenas, A., DNA methylation age at birth and childhood: performance of epigenetic clocks and characteristics associated with epigenetic age acceleration in the Project Viva cohort. Clin. Epigenetics. 2023. 15: 62.</Citation></Reference><Reference><Citation>Bi&#x144;kowski, J., Taryma&#x2010;Le&#x15b;niak, O., &#x141;uczkowska, K., Niedzwied&#x17a;, A., Lechowicz, K., Strapagiel, D., Jarczak, J. et&#xa0;al., Epigenetic activation of antiviral sensors and effectors of interferon response pathways during SARS&#x2010;CoV&#x2010;2 infection. Biomed. Pharmacother. 2022. 153: 113396.</Citation></Reference><Reference><Citation>Phetsouphanh, C., Darley, D. R., Wilson, D. B., Howe, A., Munier, C. M. L., Patel, S. K., Juno, J. A. et&#xa0;al., Immunological dysfunction persists for 8 months following initial mild&#x2010;to&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nat. Immunol. 2022. 23: 210&#x2013;216.</Citation></Reference><Reference><Citation>Tan, P. H., Ji, J., Hsing, C. H., Tan, R. and Ji, R. R., Emerging roles of type&#x2010;I interferons in neuroinflammation, neurological diseases, and long&#x2010;haul COVID. Int. J. Mol. Sci. 2022. 23: 14394.</Citation></Reference><Reference><Citation>Khan, S., Siddique, R., Hao, X., Lin, Y., Liu, Y., Wang, X., Hua, L. et&#xa0;al., The COVID&#x2010;19 infection in children and its association with the immune system, prenatal stress, and neurological complications. Int. J. Biol. Sci. 2022. 18: 707&#x2013;716.</Citation></Reference><Reference><Citation>McGlasson, S., Jury, A., Jackson, A. and Hunt, D., Type I interferon dysregulation and neurological disease. Nat. Rev. Neurol. 2015. 11: 515&#x2013;523.</Citation></Reference><Reference><Citation>Simon, A. K., Hollander, G. A. and McMichael, A., Evolution of the immune system in humans from infancy to old age. Proc. Biol. Sci. 2015. 282: 20143085.</Citation></Reference><Reference><Citation>Georgountzou, A. and Papadopoulos, N. G., Postnatal innate immune development: from birth to adulthood. Front. Immunol. 2017. 8: 957.</Citation></Reference><Reference><Citation>Costagliola, G., Spada, E. and Consolini, R., Age&#x2010;related differences in the immune response could contribute to determine the spectrum of severity of COVID&#x2010;19. Immun. Inflamm. Dis. 2021. 9: 331&#x2013;339.</Citation></Reference><Reference><Citation>Smith, N., Poss&#xe9;m&#xe9;, C., Bondet, V., Sugrue, J., Townsend, L., Charbit, B., Rouilly, V. et&#xa0;al., Defective activation and regulation of type I interferon immunity is associated with increasing COVID&#x2010;19 severity. Nat. Commun. 2022. 13: 7254.</Citation></Reference><Reference><Citation>Upasani, V., Scagnolari, C., Frasca, F., Smith, N., Bondet, V., Vanderlinden, A., Lay, S. et&#xa0;al., Decreased type I interferon production by plasmacytoid dendritic cells contributes to severe dengue. Front. Immunol. 2020. 11: 605087.</Citation></Reference><Reference><Citation>Rodero, M. P., Decalf, J., Bondet, V., Hunt, D., Rice, G. I., Werneke, S., McGlasson, S. L. et&#xa0;al., Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J. Exp. Med. 2017. 214: 1547&#x2013;1555.</Citation></Reference><Reference><Citation>Cho, S. D., Shin, H., Kim, S. and Kim, H. J., Insights on interferon&#x2010;independent induction of interferon&#x2010;stimulated genes shaping the lung's response in early SARS&#x2010;CoV&#x2010;2 infection. Heliyon. 2023. 9: e22997.</Citation></Reference><Reference><Citation>Sacchi, A., Giannessi, F., Sabatini, A., Percario, Z. A. and Affabris, E., SARS&#x2010;CoV&#x2010;2 evasion of the interferon system: can we restore its effectiveness? Int. J. Mol. Sci. 2023. 24: 9353.</Citation></Reference><Reference><Citation>Song, L., Wang, D., Abbas, G., Li, M., Cui, M., Wang, J., Lin, Z. et&#xa0;al., The main protease of SARS&#x2010;CoV&#x2010;2 cleaves histone deacetylases and DCP1A, attenuating the immune defense of the interferon&#x2010;stimulated genes. J. Biol. Chem. 2023. 299: 102990.</Citation></Reference><Reference><Citation>Schneider, W. M., Chevillotte, M. D. and Rice, C. M., Interferon&#x2010;stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 2014. 32: 513&#x2013;545.</Citation></Reference><Reference><Citation>Ryan, F. J., Hope, C. M., Masavuli, M. G., Lynn, M. A., Mekonnen, Z. A., Yeow, A. E. L., Garcia&#x2010;Valtanen, P. et&#xa0;al., Long&#x2010;term perturbation of the peripheral immune system months after SARS&#x2010;CoV&#x2010;2 infection. BMC Med. 2022. 20: 26.</Citation></Reference><Reference><Citation>Severa, M., Remoli, M. E., Giacomini, E., Ragimbeau, J., Lande, R., Uz&#xe9;, G., Pellegrini, S. et&#xa0;al., Differential responsiveness to IFN&#x2010;alpha and IFN&#x2010;beta of human mature DC through modulation of IFNAR expression. J. Leukoc. Biol. 2006. 79: 1286&#x2013;1294.</Citation></Reference><Reference><Citation>Saleh, A. Z., Fang, A. T., Arch, A. E., Neupane, D., El Fiky, A. and Krolewski, J. J., Regulated proteolysis of the IFNaR2 subunit of the interferon&#x2010;alpha receptor. Oncogene. 2004. 23: 7076&#x2013;7086.</Citation></Reference><Reference><Citation>Chen, D. Y., Khan, N., Close, B. J., Goel, R. K., Blum, B., Tavares, A. H., Kenney, D. et&#xa0;al., SARS&#x2010;CoV&#x2010;2 disrupts proximal elements in the JAK&#x2010;STAT pathway. J. Virol. 2021. 95: e0086221.</Citation></Reference><Reference><Citation>Fricke&#x2010;Galindo, I., Mart&#xed;nez&#x2010;Morales, A., Ch&#xe1;vez&#x2010;Gal&#xe1;n, L., Oca&#xf1;a&#x2010;Guzm&#xe1;n, R., Buend&#xed;a&#x2010;Rold&#xe1;n, I., P&#xe9;rez&#x2010;Rubio, G., Hern&#xe1;ndez&#x2010;Zenteno, R. J. et&#xa0;al., IFNAR2 relevance in the clinical outcome of individuals with severe COVID&#x2010;19. Front. Immunol. 2022. 13: 949413.</Citation></Reference><Reference><Citation>Scagnolari, C., Pierangeli, A., Frasca, F., Bitossi, C., Viscido, A., Oliveto, G., Scordio, M. et&#xa0;al., Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID&#x2010;19). Virus Res. 2021. 295: 198283.</Citation></Reference><Reference><Citation>Selvaggi, C., Pierangeli, A., Fabiani, M., Spano, L., Nicolai, A., Papoff, P., Moretti, C. et&#xa0;al., Interferon lambda 1&#x2013;3 expression in infants hospitalized for RSV or HRV associated bronchiolitis. J. Infect. 2014. 68: 467&#x2013;477.</Citation></Reference><Reference><Citation>Kawade, Y., Quantitation of neutralization of interferon by antibody. Methods Enzymol. 1986. 119: 558&#x2013;573.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>